版本:
中国

BRIEF-Array Biopharma announces positive top-line results from part 2 of the phase 3 columbus study of binimetinib and encorafenib

May 9 Array Biopharma Inc

* Array Biopharma announces positive top-line results from part 2 of the phase 3 Columbus study of binimetinib and encorafenib for braf-mutant melanoma

* Array Biopharma Inc - new drug application filing on track for June or July 2017

* Array - median PFS for patients on combination of binimetinib (45mg) plus encorafenib (300mg) 12.9 months versus 9.2 months for patients on encorafenib (300mg)

* Array Biopharma Inc- COMBO300 generally well-tolerated, reported dose intensity, adverse events were consistent with COMBO450 results in Columbus part 1 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐